The failed Phase III program removes a potential future revenue stream in RCC, a market with limited treatment options. For a $106.9B diversified pharma, this is a modest pipeline blow rather than a transformative event. Monitor the BALANCE trial in IBS-D/IBS-M for any remaining value in the camlipixant program, and watch for potential write-downs in the next quarterly filing. The stock may see a small negative reaction as the market prices out RCC peak sales expectations.
Price Chart
Executive Summary
GSK announced that its Phase III CALM-1 trial for camlipixant in refractory chronic cough met its primary endpoint (50mg BID at week 12), but the confirmatory CALM-2 trial failed to reach statistical significance on the same endpoint at week 24. The 25mg dose missed in both studies, and key secondary endpoints did not meet thresholds. Based on limited efficacy, GSK is discontinuing further development of camlipixant in RCC, though a Phase IIb trial in IBS-D/IBS-M continues. This is a clear pipeline setback for a mid-stage asset, though the financial impact is limited given GSK's scale ($106.9B market cap). The cross-filing context includes the 20-F annual report from March 2026, which provides baseline financial context but does not alter this filing's standalone interpretation. The cross-filing actuarial verdicts flag this as an amplifier combo (6k-activist-context + 6k-annual-context), but no activist context is present in the provided filings, so no override is applied.
Key Facts
- CALM-1 met primary endpoint (camlipixant 50mg BID showed statistically significant reduction in 24-hour cough frequency vs placebo at week 12)
- CALM-2 did not reach statistical significance on the same primary endpoint with 50mg BID at week 24
- Camlipixant 25mg BID did not reach statistical significance in either study
- Key secondary endpoints, including Chronic Cough Diary measure, did not meet target thresholds in either study
- GSK has decided not to progress further development of camlipixant in RCC
- Phase IIb BALANCE trial in IBS-D/IBS-M will continue
Financial Impact
Pipeline setback with no disclosed financial figures; R&D spend on camlipixant not quantified in filing
Risk Factors
- Complete discontinuation of camlipixant in RCC eliminates a potential growth driver in a high-unmet-need area
- BALANCE trial in IBS-D/IBS-M may also fail, rendering the entire camlipixant program worthless
- No disclosed financial impact or R&D impairment charge, leaving uncertainty about the scale of sunk costs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (GSK) — Batch item 1 | 0001654954-26-006705 |
| Document: 0001654954-26-006705-index-headers.html | 0001654954-26-006705 |
| Document: 0001654954-26-006705-index.html | 0001654954-26-006705 |
| Document: 0001654954-26-006705.txt | 0001654954-26-006705 |
| 6-K Filing (GSK) — Batch item 5 | 0001654954-26-006705 |
| Document: 0001654954-26-006705-index-headers.html | 0001654954-26-006705 |
| Document: 0001654954-26-006705-index.html | 0001654954-26-006705 |
| Document: 0001654954-26-006705.txt | 0001654954-26-006705 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $50.01 $50.22 | ▲ +0.42% | ▼ −0.40% | $47.03 (−5.96%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 11, 2026 21d ago | 6-K | $48.13 $50.22 | ▲ +4.34% | ▲ +4.56% | $47.03 (−2.29%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Aug 26, 2026 5w ago | 6-K | $51.43 $50.44 | ▼ −1.92% | ▼ −1.80% | $47.03 (−8.56%) |
Aug 24, 2026 5w ago | 6-K | $51.78 $50.25 | ▼ −2.95% | ▼ −3.42% | $47.03 (−9.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access